BioSpace News Archive

PolyPid Ltd., a late-stage biopharma company aiming to improve surgical outcomes, announced the successful completion of the production of three process validation batches of D-PLEX100 which have started stability program.

CytoSorbents Corporation, a critical care therapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, announced the re-appointment of Kathleen P. Bloch as full-time Chief Financial Officer, effective retroactively to September 2, 2023.

BioLineRx Ltd. today announced that pilot phase data from an investigator-initiated, open-label, multicenter Phase 2 clinical trial with motixafortide in first-line pancreatic ductal adenocarcinoma (PDAC) will be presented at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer taking place in Boston, Massachusetts, September 27-30, 2023.

Clearpath Technologies announced today the launch of its patient solution, PatientConnect, which it developed in partnership with leading healthcare facilities.

Repare Therapeutics to Present Preliminary Phase 1 MYTHIC Module 1 and 2 Data at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

CareDx, Inc. today announced that the Company will participate in the 2023 Cantor Global Healthcare Conference.

Ludwig, a provider of innovative medical technologies, announced Marvin S. Hausman MD has joined Ludwig Enterprises, Inc as Chief Executive Officer.

Cerecin Inc., a clinical-stage biotechnology company pioneering innovative neurotherapeutics, announced the in-license of CER-022 from the University of Alberta.

INBRAIN Neuroelectronics S.L. today announced that its Intelligent Network Modulation System has been granted Breakthrough Device Designation (BDD) from the U.S. Food & Drug Administration (FDA) as an adjunctive therapy for treating Parkinsons Disease.

Orchestra BioMed Holdings, Inc. today announced the U.S. Food and Drug Administration (“FDA”) granted approval of an investigational device exemption (“IDE”) to initiate the global pivotal BACKBEAT (BradycArdia paCemaKer with atrioventricular interval modulation for Blood prEssure treAtmenT) study evaluating the efficacy and safety of atrioventricular interval modulation (“AVIM”) therapy (also known as BackBeat CNT™).